SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

SEATTLE-（BUSINESS WIRE）-专注于开发自身免疫性和炎症性疾病创新疗法的领先临床阶段免疫治疗公司Alpine Immune Sciences，Inc.（纳斯达克股票代码：ALPN）宣布，该公司将提供RUBY-3的初步临床数据，这是一项关于povetacicept在自身免疫性肾小球肾炎（包括IgA肾病）中的1b/2a期研究，2023年11月1日至5日在宾夕法尼亚州费城举行的美国肾脏病学会（ASN）肾脏周的最新海报展示。

Following the poster presentation, the Company will host an investor event after the close of the market..

在海报展示之后，公司将在市场关闭后举办投资者活动。。

American Society of Nephrology – Kidney Week 2023

美国肾脏病学会-肾脏周2023

Date/Time: Thursday, November 2, 2023, 10:00 am – 12:00 pm ET

日期/时间：美国东部时间2023年11月2日星期四上午10:00至下午12:00

Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)

海报标题：Povetacicept，一种增强的双重BAFF/APRIL拮抗剂，用于自身抗体相关性肾小球肾炎（GN）

Poster Board Number: TH-PO1125

海报板编号：TH-PO1125

Session Name: Late-Breaking Posters

会议名称：迟到的海报

Location: Exhibit Hall, Pennsylvania Convention Center, Philadelphia

地点：费城宾夕法尼亚会议中心展览厅

Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium

主持人：James Tumlin，医学博士，埃默里大学医学院医学教授，NephroNet临床试验联盟的创始人兼首席执行官

Investor Event

投资者活动

Date/Time: Thursday, November 2, 2023, at 4:30 pm – 5:30 pm ET

日期/时间：2023年11月2日，星期四，东部时间下午4:30–5:30

Link to Webcast: https://bit.ly/48Gk8yH

网络广播链接：https://bit.ly/48Gk8yH

About Povetacicept (ALPN-303)

关于Povetacept（ALPN-303）

Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells.

Povetacicept（ALPN-303）是BAFF（B细胞活化因子）和APRIL（增殖诱导配体）细胞因子的双重拮抗剂，其通过其在活化，分化中的作用在多种自身免疫疾病的发病机理中起关键作用。和/或B细胞的存活，特别是抗体分泌细胞，以及T细胞和先天免疫细胞。

Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacicept has exhibited greater potency in preclinical studies versus wild-type TACI-based comparators, as well as other inhibitors of BAFF and/or APRIL alone and B cell depletion. Povetacicept is in development for multiple autoimmune diseases, such as systemic lupus erythematosus, autoimmune glomerulonephritis, and autoimmune cytopenias..

基于工程化的TACI（跨膜激活剂和CAML相互作用物）结构域，与野生型基于TACI的比较物以及单独的BAFF和/或APRIL的其他抑制剂和B细胞消耗相比，povetacicept在临床前研究中表现出更大的效力。Povetacicept正在开发多种自身免疫性疾病，例如系统性红斑狼疮，自身免疫性肾小球肾炎和自身免疫性血细胞减少症。。

About RUBY-3

关于RUBY-3

RUBY-3 (NCT05732402) is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is being administered subcutaneously for up to 48 weeks. Key endpoints include proteinuria, eGFR, renal response, and disease-related autoantibodies..

RUBY-3（NCT05732402）是povetacicept在自身免疫性肾小球肾炎中的多次递增剂量，多队列，开放标签的1b/2a期研究，其中povetacicept皮下给药长达48周。关键终点包括蛋白尿，eGFR，肾反应和疾病相关自身抗体。。

About Alpine Immune Sciences

关于高山免疫科学

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives.

阿尔卑斯免疫科学致力于引领新一波免疫疗法。凭借世界一流的研究和开发能力，高产的科学平台和成熟的管理团队，阿尔卑斯山正在寻求通过独特的蛋白质工程技术创造一流或一流的多功能免疫疗法，以改善患者的生活。

Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn..

阿尔卑斯已经与领先的全球生物制药公司进行了战略合作，并在开发中拥有多样化的临床和临床前候选人渠道。欲了解更多信息，请访问Twitter上的www.alpineimmunesciences.com.Follow@AlpineImmuneSci和LinkedIn。。

Forward-Looking Statements

前瞻性声明

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies; the timing of and results from clinical trials and preclinical development activities; clinical and regulatory objectives and the timing thereof; expectations regarding the sufficiency of cash, cash equivalents, restricted cash, and investments to fund our planned operations through 2025; the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates; our ability to achieve additional milestones in our collaborations and proprietary programs; the progress and potential of our ongoing development programs; the timing of our public presentations and potential publication of future clinical data; the efficacy of our clinical trial designs; anticipated enrollment in our clinical trials and the timing thereof; expectations regarding our ongoing collaborations; and our ability to successfully develop and achieve milestones in our development programs.

本版本包含1933年“证券法”第27A条，“1934年证券交易所法”第21E条和1995年“私人证券诉讼改革法”含义内的前瞻性陈述。这些前瞻性陈述并非基于历史事实，包括有关我们平台技术和潜在疗法的陈述；临床试验和临床前开发活动的时间安排和结果；临床和监管目标及其时机；对现金，现金等价物，限制现金和投资的充足性的期望，为我们计划的运营提供资金，直至2025年；我们的产品候选人的潜在功效，安全性，未来发展计划，可寻址市场，监管成功和商业潜力；我们在合作和专有计划中实现其他里程碑的能力；我们正在进行的发展计划的进展和潜力；我们公开演讲的时间安排和未来临床数据的潜在发布；我们的临床试验设计的功效；预期参加我们的临床试验及其时间；对我们正在进行的合作的期望；以及我们成功开发和实现发展计划里程碑的能力。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different f.

前瞻性陈述通常包括本质上具有预测性并取决于或指代未来事件或条件的陈述，并包括诸如“可能”，“将会”，“应该”，“期望”，“计划”，“意图”等词语。以及其他类似的表达方式。这些前瞻性陈述基于当前的假设，这些假设涉及风险，不确定性和其他可能导致实际结果，事件或发展实质性不同的因素f。